Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth R Plimack

Showing results (51-60 of 209) with videos related to

Pageof 21
Sort By:
Gynecologic Oncology|October 29, 2005
Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG studyHoward S Hochster, Elizabeth R Plimack, John Mandeli, et al.
The Oncologist|October 6, 2022
Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell CarcinomaKevin K Zarrabi, Elizabeth Handorf, Benjamin Miron, et al.
Cancer Treatment Reviews|July 10, 2017
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their managementMario Sznol, Michael A Postow, Marianne J Davies, et al.
The American Journal of Managed Care|April 19, 2018
Provider and patient burdens of obtaining oral anticancer medicationsDaniel M Geynisman, Caitlin R Meeker, Jamie L Doyle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2016
National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder CancerSumanta Kumar Pal, Neeraj Agarwal, Stephen Anthony Boorjian, et al.
European Urology Focus|May 9, 2022
A Seat at the Table: The Correlation Between Female Authorship and Urology Journal Editorial Board MembershipMegan Prunty, Stephen Rhodes, Helen Sun, et al.
European Urology Oncology|July 6, 2022
Neoadjuvant Chemotherapy with Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients with Muscle-invasive Bladder Cancer: A Retrospective Age-stratified Analysis on Safety and EfficacyGregory Hemenway, Bianca Lewis, Pooja Ghatalia, et al.
European Urology|June 9, 2018
Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based AnalysisShreyas S Joshi, Elizabeth A Handorf, Matthew Zibelman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2004
Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology GroupHoward Hochster, Elizabeth R Plimack, Carolyn D Runowicz, et al.
Cancer Immunology Research|April 26, 2014
PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resectionAlexander W MacFarlane, Mowafaq Jillab, Elizabeth R Plimack, et al.
Pageof 21

Showing results (51-60 of 209) with videos related to

Sort By:
Pageof 21
Gynecologic Oncology|October 29, 2005
Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG studyHoward S Hochster, Elizabeth R Plimack, John Mandeli, et al.
The Oncologist|October 6, 2022
Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell CarcinomaKevin K Zarrabi, Elizabeth Handorf, Benjamin Miron, et al.
Cancer Treatment Reviews|July 10, 2017
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their managementMario Sznol, Michael A Postow, Marianne J Davies, et al.
The American Journal of Managed Care|April 19, 2018
Provider and patient burdens of obtaining oral anticancer medicationsDaniel M Geynisman, Caitlin R Meeker, Jamie L Doyle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2016
National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder CancerSumanta Kumar Pal, Neeraj Agarwal, Stephen Anthony Boorjian, et al.
European Urology Focus|May 9, 2022
A Seat at the Table: The Correlation Between Female Authorship and Urology Journal Editorial Board MembershipMegan Prunty, Stephen Rhodes, Helen Sun, et al.
European Urology Oncology|July 6, 2022
Neoadjuvant Chemotherapy with Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients with Muscle-invasive Bladder Cancer: A Retrospective Age-stratified Analysis on Safety and EfficacyGregory Hemenway, Bianca Lewis, Pooja Ghatalia, et al.
European Urology|June 9, 2018
Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based AnalysisShreyas S Joshi, Elizabeth A Handorf, Matthew Zibelman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2004
Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology GroupHoward Hochster, Elizabeth R Plimack, Carolyn D Runowicz, et al.
Cancer Immunology Research|April 26, 2014
PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resectionAlexander W MacFarlane, Mowafaq Jillab, Elizabeth R Plimack, et al.
Pageof 21